Trials / Unknown
UnknownNCT03539367
Effect of Acetazolamide on Lung Water Content by Ultrasound in Lowlanders Older Than 40 Years at Altitude
Effect of Acetazolamide on Lung Water Content by Ultrasound in Lowlanders Older Than 40 Years at Altitude: A Randomized, Placebo-controlled, Double-blind Parallel Trial
- Status
- Unknown
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 100 (estimated)
- Sponsor
- University of Zurich · Academic / Other
- Sex
- All
- Age
- 40 Years – 75 Years
- Healthy volunteers
- Accepted
Summary
Randomized, placebo controlled trial evaluating the effect of acetazolamide on lung water content by ultrasound in lowlanders older than 40 years travelling from 760 m to 3'100 m.
Detailed description
This is a randomized, placebo-controlled, double-blind parallel trial evaluating the effect of preventive acetazolamide intake on lung water content by ultrasound in lowlanders older than 40 years travelling to altitude. Participants living in the Bishkek area, Kyrgyzstan (760m), will be transferred by car within 4h to the Tuja Ashu high altitude clinic (3'100 m), and stay there for 2 days. Acetazolamide 375mg/day (or placebo), will be administered before departure at 760 m and during the stay at altitude. Outcomes will be assessed during the stay at 3'100 m. An interim analysis will be carried out when 200 participants will have completed the study and/or after the first year. The Peto's method will be used and the trial will be stopped when pre-specified futility boundaries were crossed.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ACETAZOLAMIDE oral capsule | Administration of 1x125mg acetazolamide in the morning, 2x125mg in the evening, starting 24 hours before departure to 3'100m |
| DRUG | Placebo oral capsule | Administration of equally looking placebo capsules in the morning and evening, starting 24 hours before departure to 3'100m |
Timeline
- Start date
- 2018-06-01
- Primary completion
- 2022-12-31
- Completion
- 2022-12-31
- First posted
- 2018-05-29
- Last updated
- 2022-11-02
Locations
1 site across 1 country: Kyrgyzstan
Source: ClinicalTrials.gov record NCT03539367. Inclusion in this directory is not an endorsement.